Brand Rx Makers Push Trade Deal That Restricts U.S. Ability To Curb Rx Spending

Just as the country is on the verge of a significant increase in drug spending, brand-drug makers are lobbying for a trade deal that could severely constrain the ability of Medicare to curb drug prices, consumer groups warn. Early this year, the Obama administration backed off some of its proposals in the pharmaceutical annex of the Trans-Pacific Partnership to appease consumer groups, but those groups say the deal would still constrain drug price controls in Part B (medical), which mostly...